Immunogenicity and safety of a multi-human dose formulation of Biological E’s 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14®) administered to 6–8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled

Authors

Prashanth Siddaiah
SubbaReddy Gunneri
Ramesh V. Matur (ORCID: https://orcid.org/0000-0001-5891-2684)
Piyush Paliwal
Subhash Thuluva (ORCID: https://orcid.org/0000-0002-9099-420X)
Rammohan Reddy Mogulla (ORCID: https://orcid.org/0000-0001-6638-7701)
Kamal Thammireddy (ORCID: https://orcid.org/0009-0007-7614-4026)
Niranjana Mahantshetti
Kalyan Kumar Peta
Ramesh Kumar Banala

Institutions

Biological E (India) (IN)
KLE Society Hospital (IN)
King George Hospital (IN)
JSS Medical College and Hospital (IN)

Publication Details

Journal: Frontiers in Immunology
Published: 2025-04-07
DOI: https://doi.org/10.3389/fimmu.2025.1550227
Citations: 3
Primary Topic: Pneumonia and Respiratory Infections
Type: article
Field-Weighted Citation Impact: 4.06

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Immunogenicity and safety of a multi-human dose formulation of Biological E’s 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14®) administered to 6–8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled

Prashanth Siddaiah, SubbaReddy Gunneri, Ramesh V. Matur, Piyush Paliwal et al.

Apr 7, 2025

3 citations

Frontiers in Immunology

Pneumonia and Respiratory Infections

4.06

article

Immunogenicity and safety of a multi-human dose formulation of Biological E’s 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14®) administered to 6–8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled

Prashanth Siddaiah, SubbaReddy Gunneri, Ramesh V. Matur, Piyush Paliwal, Subhash Thuluva, Rammohan Reddy Mogulla, Kamal Thammireddy, Niranjana Mahantshetti, Kalyan Kumar Peta, Ramesh Kumar Banala

April 7, 2025article en

3 citations

Abstract

No abstract available for this paper.

Frontiers in ImmunologyVol. 16

Biological E (India) (IN), KLE Society Hospital (IN), King George Hospital (IN), JSS Medical College and Hospital (IN)

Openalex Percentile: Top 7%

Pneumonia and Respiratory Infections

4.06

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Immunogenicity and safety of a multi-human dose formulation of Biological E’s 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14®) administered to 6–8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled — Prashanth Siddaiah, SubbaReddy Gunneri, et al. · Frontiers in Immunology (2025) | TGRS Research Map | TGRS